Document Detail

T cell costimulatory and inhibitory receptors as therapeutic targets for inducing anti-tumor immunity.
MedLine Citation:
PMID:  17305478     Owner:  NLM     Status:  MEDLINE    
Central to the normal function of the immune system is its ability to distinguish between self and non-self since failure to do so could provoke the onset of autoimmune disease. To avoid this possibility, the immune system employs several processes that include, negative selection, peripheral tolerance, and limiting DC antigen priming of naïve T cells to the lymph nodes. Naïve T cells must receive two independent signals from these antigen-presenting cells (APC) that other cells cannot provide if they are to become productively activated. The first is antigen-specific and occurs when T cell antigen receptors encounter the appropriate antigen-MHC complex on the APC--Signal 1. A second, antigen-independent signal is delivered through a T cell costimulatory molecule that engages its APC-expressed ligands--Signal 2. In the absence of a costimulatory signal T cells typically enter a state of anergy. Furthermore, the extent to which T cell activation occurs can be held in check through specific inhibitory receptors expressed on T cells. Understanding the basic mechanisms of how T cell activation is regulated has led to the development of therapeutic approaches for targeting T cell costimulatory and inhibitory pathways for turning on, or preventing the turning off immune responses in subjects with cancer. In this review we will discuss several T cell costimulatory and inhibitory pathways known to influence the development of anti-tumor immunity and how experimental manipulation of these signaling pathways has led to the generation of protective, or curative anti-tumor immunity in mice and humans.
Jeurgen Foell; Becker Hewes; Robert S Mittler
Related Documents :
24832448 - The balancing act of neutrophils.
17305478 - T cell costimulatory and inhibitory receptors as therapeutic targets for inducing anti-...
22414338 - The impact of obesity on the immune response to infection.
11495718 - Signal transduction via the growth hormone receptor.
16428838 - Activation of murine peritoneal macrophages by water-soluble extracts of bursaphelenchu...
11281558 - Gastrin inhibits cholangiocarcinoma growth through increased apoptosis by activation of...
Publication Detail:
Type:  Journal Article; Review    
Journal Detail:
Title:  Current cancer drug targets     Volume:  7     ISSN:  1873-5576     ISO Abbreviation:  Curr Cancer Drug Targets     Publication Date:  2007 Feb 
Date Detail:
Created Date:  2007-02-19     Completed Date:  2007-03-20     Revised Date:  2011-03-30    
Medline Journal Info:
Nlm Unique ID:  101094211     Medline TA:  Curr Cancer Drug Targets     Country:  Netherlands    
Other Details:
Languages:  eng     Pagination:  55-70     Citation Subset:  IM    
Department of Pediatrics, Hematology and Oncology and Center for Cell and Gene Therapy, Martin Luther University, Halle-Wittenburg, Germany.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Antigen-Presenting Cells / physiology
Antigens, CD / physiology
Antigens, CD137 / physiology
Antigens, CD28 / physiology*
Antigens, CD80 / physiology*
Antigens, CD86 / physiology
Antigens, Differentiation / physiology
Intercellular Signaling Peptides and Proteins / physiology
Lymphocyte Activation*
Neoplasms / immunology*
OX40 Ligand / physiology
Signal Transduction
T-Lymphocytes / immunology*
Reg. No./Substance:
0/Antigens, CD; 0/Antigens, CD137; 0/Antigens, CD28; 0/Antigens, CD80; 0/Antigens, CD86; 0/Antigens, Differentiation; 0/B7-DC antigen; 0/CD274 protein, human; 0/Intercellular Signaling Peptides and Proteins; 0/OX40 Ligand; 0/cytotoxic T-lymphocyte antigen 4

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine

Previous Document:  Cellular and molecular mechanisms of tumor-induced T-cell tolerance.
Next Document:  Targeting of Jak/STAT pathway in antigen presenting cells in cancer.